Sana Biotechnology Announces the Acceptance of Four

SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Late-breaking poster details:

Title:Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells
Session Title:Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date:Wednesday, April 19, 2023
Session Time:9:00 a.m. - 12:30 p.m. ET
Location:Poster Section 35
Abstract Number:LB311


Poster details:

Title:Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes
Session Category:Experimental and Molecular Therapeutics
Session Title:Gene and Vector-based Therapy
Session Date:Monday, April 17, 2023
Session Time:1:30 p.m. - 5:00 p.m. ET
Location:Poster Section 16
Abstract Number:2734


Title:Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome
Session Category:Experimental and Molecular Therapeutics
Session Title:Gene and Vector-based Therapy
Session Date:Monday, April 17, 2023
Session Time:1:30 p.m. - 5:00 p.m. ET
Location:Poster Section 16
Abstract Number:2735


Title:Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge
Session Category:Immunology
Session Title:CAR T-cell Therapy 2
Session Date:Tuesday, April 18, 2023
Session Time:9:00 a.m. - 12:30 p.m. ET
Location:Poster Section 23
Abstract Number:4091


Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR Online Itinerary Planner located here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking abstract text will be posted to the AACR Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for the Company’s participation at the 2023 American Association for Cancer Research Annual Meeting; expectations for the Company’s presentations at such meeting, including the content of such presentations; and expectations for the publication of abstracts. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 2, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com


Sana Biotechnology Announces the Acceptance of Four

TIN LIÊN QUAN

Tango Therapeutics to Highlight Preclinical Data on

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster...

Mablink Bioscience to Present Promising Preclinical Data

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

Molecular Partners to Present at SVB Leerink Global

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

REE Automotive, Ltd. Announces Date for Fourth Quarter 2022

TEL-AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- REE Automotive, Ltd. (NASDAQ: REE) (“REE” or the “Company”), an automotive technology company and...

THỦ THUẬT HAY

Trọn bộ Full key active office 2016 bản quyền mới nhất 2023 [ hoạt động 24/7]

Bạn đang muốn tìm kiếm bộ key active office 2016 nhưng không tìm kiếm được nguồn đáng tin cậy. Mua bản chính thức từ Microsoft hoặc các đại lý phối thì giá rất cao. Nếu không chia sẻ với nhiều người thì rất lãng phí.

Hỏi và đáp 360 độ tổng hợp về 4G Viettel

Thời gian gần đây, 4G Viettel trở thành một từ khóa nóng nhất với người dùng yêu thích công nghệ trên toàn quốc. Khắp các tỉnh thành, khách hàng của Viettel nô nức đi đổi sang sim 4G. Vậy đâu là lý do khiến khách hàng

+ 99 ý tưởng trang trí nhà ngày Tết sang trọng, độc đáo nhất năm 2023

Bên cạnh việc chuẩn bị đồ ăn thức uống ngày Tết thì trang trí nhà ngày Tết cũng là một phần không thể thiếu. Chỉ cần một vài thao tác trang trí nhà đơn giản sẽ giúp không gian nhà bạn ngập tràn không khí Tết, đón một

Cách đóng bảo hiểm y tế online nhanh chóng, tiện lợi

Hiện tại, đã có khá nhiều cách cách đóng bảo hiểm y tế online tại nhà vừa tiết kiệm thời gian, vừa tránh tiếp xúc với nhiều người.

[Mac] Dùng Vox để nghe Youtube

Vox là phần mềm miễn phí trên App Store. Mình vẫn dùng nó để nghe FLAC và các chuẩn âm thanh mà iTune không hỗ trợ. Mình cũng thường xuyên nghe nhạc trên Youtube. Hồi xưa chưa biết...

ĐÁNH GIÁ NHANH

Trên tay máy bơm lốp "dạo" tích hợp nguồn dự phòng Campbell Hausfeld CC2300

Điểm đặc biệt về chiếc máy bơm lốp di động Campbell Hausfeld CC2300 này là nó có tích hợp một bộ pin 12V, 7Ah để giúp nó có thể hoạt động một cách độc lập, thay vì phải đi dây loằn ngoằn để lấy nguồn từ lỗ mồi thuốc

Đánh giá chi tiết Xiaomi Mi 5s: máy đẹp, hiệu năng mạnh, pin tốt

Xiaomi Mi 5s có vẻ như đang bị rơi vào lãng quên, nhưng thực sự thì đây vẫn là chiếc điện thoại được đánh giá rất nên mua vào thời điểm này

Đánh giá chi tiết Volkswagen Tiguan Allspace: Xứng với giá 1,729 tỉ đồng

Volkswagen Việt Nam chọn phân phối duy nhất bản 7 chỗ VW Tiguan Allspace giá 1,729 tỉ đồng nhằm phát huy những lợi thế 'độc tôn' mà các đối thủ khác không có được.